130 related articles for article (PubMed ID: 37981037)
1. Melancholic features and treatment outcome to selective serotonin reuptake inhibitors in major depressive disorder: A re-analysis of the STAR*D trial.
Szmulewicz A; Valerio MP; Lomastro J; Martino DJ
J Affect Disord; 2024 Feb; 347():101-107. PubMed ID: 37981037
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
[TBL] [Abstract][Full Text] [Related]
3. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
McGrath PJ; Khan AY; Trivedi MH; Stewart JW; Morris DW; Wisniewski SR; Miyahara S; Nierenberg AA; Fava M; Rush AJ
J Clin Psychiatry; 2008 Dec; 69(12):1847-55. PubMed ID: 19026268
[TBL] [Abstract][Full Text] [Related]
4. Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study.
Ishak WW; Christensen S; Sayer G; Ha K; Li N; Miller J; Nguyen JM; Cohen RM
J Clin Psychiatry; 2013 Mar; 74(3):256-61. PubMed ID: 23561231
[TBL] [Abstract][Full Text] [Related]
5. Impact of fatigue on outcome of selective serotonin reuptake inhibitor treatment: secondary analysis of STAR*D.
Ferguson M; Dennehy EB; Marangell LB; Martinez J; Wisniewski SR
Curr Med Res Opin; 2014 Oct; 30(10):2109-18. PubMed ID: 24949937
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
[TBL] [Abstract][Full Text] [Related]
7. Melancholic features in major depression - a European multicenter study.
Dold M; Bartova L; Fugger G; Kautzky A; Mitschek MMM; Fabbri C; Montgomery S; Zohar J; Souery D; Mendlewicz J; Serretti A; Kasper S
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110285. PubMed ID: 33609603
[TBL] [Abstract][Full Text] [Related]
8. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
Gilmer WS; Gollan JK; Wisniewski SR; Howland RH; Trivedi MH; Miyahara S; Fleck J; Thase ME; Alpert JE; Nierenberg AA; Warden D; Fava M; Rush AJ
J Clin Psychiatry; 2008 Aug; 69(8):1246-56. PubMed ID: 18681756
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
10. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.
Zisook S; Trivedi MH; Warden D; Lebowitz B; Thase ME; Stewart JW; Moutier C; Fava M; Wisniewski SR; Luther J; Rush AJ
J Affect Disord; 2009 Sep; 117(1-2):63-73. PubMed ID: 19217668
[TBL] [Abstract][Full Text] [Related]
11. A quantitative review on outcome-to-antidepressants in melancholic unipolar depression.
Valerio MP; Szmulewicz AG; Martino DJ
Psychiatry Res; 2018 Jul; 265():100-110. PubMed ID: 29702301
[TBL] [Abstract][Full Text] [Related]
12. Response to antidepressants in major depressive disorder with melancholic features: the CRESCEND study.
Yang SJ; Stewart R; Kang HJ; Kim SY; Bae KY; Kim JM; Jung SW; Lee MS; Yim HW; Jun TY
J Affect Disord; 2013 Jan; 144(1-2):42-50. PubMed ID: 22840632
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.
Mrazek DA; Biernacka JM; McAlpine DE; Benitez J; Karpyak VM; Williams MD; Hall-Flavin DK; Netzel PJ; Passov V; Rohland BM; Shinozaki G; Hoberg AA; Snyder KA; Drews MS; Skime MK; Sagen JA; Schaid DJ; Weinshilboum R; Katzelnick DJ
J Clin Psychopharmacol; 2014 Jun; 34(3):313-7. PubMed ID: 24743713
[TBL] [Abstract][Full Text] [Related]
14. Initial Severity Effects on Residual Symptoms in Response and Remission: A STAR*D Study During and After Failed Citalopram Treatment.
Madhoo M; Levine SZ
J Clin Psychopharmacol; 2015 Aug; 35(4):450-3. PubMed ID: 26066336
[TBL] [Abstract][Full Text] [Related]
15. Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.
Kornstein SG; Toups M; Rush AJ; Wisniewski SR; Thase ME; Luther J; Warden D; Fava M; Trivedi MH
J Womens Health (Larchmt); 2013 Feb; 22(2):121-31. PubMed ID: 23398127
[TBL] [Abstract][Full Text] [Related]
16. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
Iosifescu DV; Nierenberg AA; Mischoulon D; Perlis RH; Papakostas GI; Ryan JL; Alpert JE; Fava M
J Clin Psychiatry; 2005 Aug; 66(8):1038-42. PubMed ID: 16086620
[TBL] [Abstract][Full Text] [Related]
17. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
[TBL] [Abstract][Full Text] [Related]
18. Emulating a Target Trial of Dynamic Treatment Strategies for Major Depressive Disorder Using Data From the STAR∗D Randomized Trial.
Szmulewicz AG; Wanis KN; Perlis RH; Hernández-Díaz S; Öngür D; Hernán MA
Biol Psychiatry; 2023 Jun; 93(12):1127-1136. PubMed ID: 36639294
[TBL] [Abstract][Full Text] [Related]
19. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
[TBL] [Abstract][Full Text] [Related]
20. Do atypical features affect outcome in depressed outpatients treated with citalopram?
Stewart JW; McGrath PJ; Fava M; Wisniewski SR; Zisook S; Cook I; Nierenberg AA; Trivedi MH; Balasubramani GK; Warden D; Lesser I; John Rush A
Int J Neuropsychopharmacol; 2010 Feb; 13(1):15-30. PubMed ID: 19341509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
